IN THE NOW AND IN THE KNOW
verdemedica-2.jpg

POMELLA® : NEW RESEARCH - CARDIO-METABOLIC HEALTH

Natural Products INSIDER, October 2016 - Researchers with the Srikot Research Institute studied the effects of Pomella® Extract (from Verdure Sciences) in patients (20-60 years of age) with myocardial infarction in conjunction with regular prescribed medications. The study determined the effects of 300 mg/Pomella twice daily for 30 days on biomedical parameters like HDL, total cholesterol, triglycerides, LDL, non-HDL cholesterol, serum homocysteine, hs-CRP, and OX-LDL as an add-on with regular medication showing improved antioxidant status of the blood biomarkers associated with cardiac health.

To read the entire article click here.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Please note that the physiological activity of the ingredient(s) described herein is supported by the referenced clinical trial reports. Marketers of finished products containing the ingredient(s) described herein are responsible for determining whether claims made for such products are lawful and in compliance with the laws of the country in which they will market the products.
Verdure Sciences, Longvida (US Patent 9192644, EP Patent 1993365; additional patents pending), Bacognize, Calzbone, Pomella (US Patents 7638640, 7897791, and 7919636), Tinofend, and WokVel are registered trademarks of Verdure Sciences, Inc. Ashwamax, Bacoboost, Cinnagest, Factor21, Lutevida, Maplifa, Rejuna, Thymocid, Gingerize, VBATS, VerdeMedica, and SLP/SLCP are trademarks of Verdure Sciences, Inc. All Rights Reserved. © 2017 Verdure Sciences.
For our most current patent information, please visit: www.vs-corp.com/ip